Method for determining an analyte of interest by frequency detection - Patents.com
By employing modified nanopores with distinct resonant frequencies in two-dimensional materials and detecting frequency shifts, the method addresses the ambiguity in nanopore detection, enabling precise analyte quantification and identification in biological samples.
Patent Information
- Application Number
- JP2024530483
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-24
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-15
AI Technical Summary
Existing nanopore-based detection methods struggle with ambiguity in signal interpretation due to their single-molecule nature, making it difficult to accurately determine the number of functional pores and analyte concentrations, especially in low and high concentrations, and lack clarity in distinguishing analyte binding events.
The method involves using modified nanopores embedded in two-dimensional materials with distinct resonant frequencies, applying an AC current to detect frequency shifts between the nanopore and modified nanopore, allowing for precise determination of analytes by frequency detection.
This approach enhances the accuracy of analyte detection by providing clear frequency shifts that enable precise quantification and identification of analytes, such as proteins and small molecules, even in complex biological samples.
Smart Images

Figure 2024542517000001 
Figure 2024542517000002 
Figure 2024542517000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for determining an analyte of interest by frequency detection and uses thereof, modified nanopores, analytical systems, kits and uses thereof. [Background technology]
[0002] Biologically active components, such as small molecules, proteins, antigens, immunoglobulins, and nucleic acids, are involved in numerous biological processes and functions. Thus, disturbances in the levels of such components can lead to disease or accelerate disease progression. For this reason, much effort has been devoted to developing reliable methods to rapidly detect and identify biologically active components for use in patient diagnosis and treatment. For example, detection of proteins or small molecules in blood or urine samples can assess the metabolic status of a patient. Similarly, detection of antigens in blood or urine samples can identify pathogens to which a patient has been exposed and allow appropriate treatment to be administered. It is further beneficial to be able to determine the concentration of an analyte in a solution. For example, determining the concentration of a blood or urine component allows the component to be compared to a reference value, facilitating further evaluation of the patient's health status.
[0003] There are numerous detection and identification methods. For example, US202110088511 describes the basic concept of a tag captured by biotin-streptavidin interaction and a large protein in the nanopore resulting in a charged construct captured in a single nanopore. Each tag is designed to have a different ionic current through the pore depending on the degree of blockage in the pore. Insertion into the pore is based on the surrounding proteins and / or chemicals on top of the pore and their respective behavior and / or interaction with the surrounding medium.
[0004] Typical levels of AC current are in the range of 1 Hz when sequencing experiments are performed and the readout frequency is 1000 Hz.
[0005] Modifying the nanopore is also seen in sequencing technologies (e.g., Genia) where an enzyme (e.g., polymerase) is tagged onto the nanopore itself.
[0006] In this system, the open channel after pore insertion, capture of biotin-streptavidin-tag-protein constructs, and further modification events can be confirmed by different current levels. The current levels are generated through the respective AC. Switching AC (alternating current, positive / negative) gives two current levels that reflect the state of the pore and the strength and direction of the respective ion flow (positively charged ions to the negative electrode and vice versa).
[0007] The current readout concept of experimental (AC) values is very useful when only one analyte needs to be detected. The composition of the buffer used can be very carefully adjusted and optimized, since the raw signal of the captured construct is often difficult to interpret. The current concept does not incorporate the concept of tag uniqueness or detection of further binding and / or modification events of the construct, which would indeed be very interesting in the case where multiplexing is desired and digital counting of active binding / pore sites and bound sites / pores. Furthermore, nanopores, due to their single molecule nature, can generate ambiguous and difficult to interpret signals, so that it is not possible to find out with the desired accuracy how many functional pores there are. This is also important when low and high concentrations of analyte are present, which is only possible if the number of free binding sites, binders and covered binding sites can be counted and / or determined.
[0008] Analyte binding or generally modification events are manifested only in a shift in the current level, which is often misleading and needs to be made clearer by another dimension of information.
[0009] However, there remains a need for improved detection and identification methods.
[0010] The present invention relates to a method for determining analytes of interest, such as steroids, peptides, proteins and other types of analytes, for example in biological samples, by frequency detection. The present invention further relates to modified nanopores, analytical systems and uses thereof.
[0011] It is an object of the present invention to provide a method for determining an analyte of interest by frequency detection, uses thereof, a modified nanopore, an analytical system and uses thereof.
[0012] This object is solved by the subject matter of the independent claims. Further embodiments are subject to the dependent claims. Summary of the Invention
[0013] In the following, the present invention relates to the following aspects: In a first aspect, the present invention provides a method for determining an analyte of interest by frequency detection, comprising: a) providing a nanopore, the nanopore embedded in a two-dimensional material, having a first resonant frequency f1 and a second resonant frequency f AC applying an AC current having a b) providing a modified nanopore, the modified nanopore being embedded in the two-dimensional material and having a second resonant frequency f2, and having an AC frequency f AC An AC current having a magnitude of f AC >f1>f2, the modified nanopore containing an analyte of interest; c) detecting a frequency shift Δ between the first frequency and the second frequency; and d) using the frequency shift Δ to determine the analyte of interest.
[0014] In a second aspect, the present invention relates to the use of the method of the first aspect of the invention for determining an analyte of interest.
[0015] In a third aspect, the present invention provides a modified nanopore for use in a method of the first aspect of the invention for determining an analyte of interest, comprising: - protein nanopores or solid-state nanopores, - Optionally, a binder, and - an analyte of interest, the modified nanopore containing the analyte.
[0016] In a fourth aspect, the present invention provides a method for producing a pharmaceutical composition comprising the steps of: a nanopore embedded in a two-dimensional material and having a first resonant frequency f1 and an AC frequency f AC A nanopore to which an AC current having a modified nanopore, the modified nanopore being embedded in a two-dimensional material and having a second resonant frequency f2, the second resonant frequency f being at an AC frequency f AC and a modified nanopore to which an AC current having a f AC >f1>f2, the modified nanopore contains an analyte of interest; The analytical system is configured to detect a frequency shift Δ between the first frequency and the second frequency and to use the frequency shift Δ to determine the analyte of interest.
[0017] In a sixth aspect, the present invention provides a kit suitable for carrying out the method of the first aspect of the invention, comprising: - one or more reagents for forming a two-dimensional material; - one or more reagents for forming a nanopore; - one or more reagents for forming a modified nanopore, and - optionally a component selected from the group consisting of calibrators, buffers, additives, consumables, evaluation algorithms, and combinations thereof.
[0018] In a seventh aspect, the present invention relates to the use of the kit of the fifth aspect of the invention for determining an analyte of interest by frequency detection. [Brief description of the drawings]
[0019] [Figure 1] Figure 1A shows the general principle of the experimental current / magnetic driven readout of a modified nanopore (biotin-streptavidin-protein in a lipid bilayer) with a time-dependent readout shown, while Figure 1B shows the tag used to generate a defined voltage level in the nanopore. [Diagram 2] The general principle of the experimental current / magnetic driven readout of a modified nanopore (biotin-streptavidin-protein in a lipid bilayer) is shown, with a time-dependent readout demonstrated. [Diagram 3] We present a method by which a nanopore workflow can be influenced by an external field (magnetic or electric field) and thus distorted, resulting in a change in current. [Figure 4] The general principle of the experimental current / magnetic driven readout of a modified nanopore (biotin-streptavidin-protein in a lipid bilayer) is shown, with a time-dependent readout demonstrated. [Figure 5A] The RAW signal (current versus time) of the modified nanopore is shown. [Figure 5B] 5A shows the signal (amplitude vs. frequency) for each of the regions described in FIG. 5A after Fourier transformation of the raw signal described in FIG. 5A (FFT signal). [Figure 6-1] The raw signal (current versus time) of an experiment similar to that of FIG. 5 is shown. [Figure 6-2] 5 shows the FFT signal (amplitude vs. frequency) of an experiment similar to that of FIG. [Figure 7A] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. [Figure 7B] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. [Figure 8A] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. [Figure 8B] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. [Figure 8C] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. [Figure 8D] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. [Figure 8E] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. [Figure 9A] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. The frequency-dependent FFT analysis at fAC = 1 Hz is shown. [Figure 9B] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. The frequency-dependent FFT analysis at fAC = 1 Hz is shown. [Figure 9C] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. The frequency-dependent FFT analysis at fAC = 1 Hz is shown. [Figure 10A] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. The frequency-dependent FFT analysis at fAC=1000 Hz is shown. [Figure 10B] The raw signal (current vs. time) and the FFT signal (amplitude vs. frequency) of the modified nanopore are shown. The frequency-dependent FFT analysis at fAC=1000 Hz is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] Before the present invention is described in detail below, it should be understood that the present invention is not limited to the specific embodiments and examples described herein, which may vary.It should also be understood that the terms used herein are only intended to describe specific embodiments, and are not intended to limit the scope of the present invention, which is limited only by the scope of the appended claims.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.
[0021] Several documents are cited in the body of this specification. Each document cited in this specification (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, is incorporated herein by reference in its entirety. In the event of a discrepancy between the definitions or teachings of such incorporated references and those set forth in this specification, the body of this specification shall control.
[0022] Each element of the present invention will be described below. Although these elements are listed with specific embodiments, it should be understood that they can be combined in any manner and in any number to create additional embodiments. The various described examples and preferred embodiments should not be interpreted to limit the present invention to only the embodiments explicitly described. This specification should be understood to support and encompass embodiments combining the explicitly described embodiments with any number of the disclosed and / or preferred elements. Furthermore, any permutation and combination of all elements described in this application should be considered to be disclosed by the description of this application unless the context indicates otherwise.
[0023] definition It will be understood that the word "comprise", and variations such as "comprises" and "comprising", imply the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integers or steps or group of integers or steps. The terms "including" and "comprising" may be used interchangeably.
[0024] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.
[0025] Percentages, concentrations, amounts, and other numerical data may be expressed or presented herein in a "range" format. It should be understood that such range formats are used merely for convenience and brevity, and thus should be interpreted flexibly to include not only the numerical values expressly recited as boundaries of the range, but also to include all of the individual numerical values or subranges subsumed within the range as if each numerical value and subrange were expressly recited. By way of illustration, a numerical range of "4%-20%" should be interpreted to include not only the explicitly recited value of 4%-20%, but also the individual values and subranges within the indicated range. Thus, this numerical range includes individual values such as 4, 5, 6, 7, 8, 9, 10, ... 18, 19, 20%, and individual subranges such as 4-10%, 5-15%, 10-20%, etc. This same principle also applies to ranges that recite minimum or maximum values. Moreover, such interpretation should be applied regardless of the breadth of the range or the characteristics being recited.
[0026] The term "about," when used in connection with a numerical value, is meant to include numerical values in a range having a lower limit of 5% less than the stated numerical value and an upper limit of 5% greater than the stated numerical value.
[0027] In the context of this disclosure, the terms "analyte", "analyte molecule", or "analyte of interest" are used interchangeably to refer to a chemical species to be analyzed. A chemical species, i.e., an analyte, can be any type of molecule present in an organism, including, but not limited to, nucleic acids (e.g., DNA, mRNA, miRNA, rRNA, etc.), amino acids, peptides, proteins (e.g., cell surface receptors, cytosolic proteins, etc.), metabolites or hormones (e.g., testosterone, estrogen, estradiol, etc.), fatty acids, lipids, carbohydrates, steroids, ketosteroids, secosteroids (e.g., vitamin D), molecules characterized by a particular modification of another molecule (e.g., sugar moieties or phosphoryl residues on proteins, methyl residues on genomic DNA), or substances internalized by an organism (e.g., therapeutic drugs, drugs of abuse, toxins, etc.), or metabolites of such substances. Such analytes may serve as biomarkers. In the context of the present invention, the term "biomarker" refers to a substance in a biological system that is used as an indicator of the biological state of that system.
[0028] As used herein, the term "determining" an analyte of interest refers to the quantification and / or qualification of the analyte of interest, e.g., determining the presence of the analyte of interest and / or measuring the level of the analyte of interest in a sample.
[0029] The term "nanopore" can refer to a small nanometer-scale pore in a thin membrane or two-dimensional material (e.g., a lipid bilayer) or formed as a small nanometer-scale pore in a two-dimensional plane of a solid (e.g., a glass nanopore). Nanopore and pore can be used interchangeably.
[0030] As used herein, the term "construct" is a broad term and should be given its ordinary and customary meaning to those of skill in the art and should not be limited to any specific or special meaning. The term can refer, in particular, but not exclusively, to a modified nanopore embedded in a two-dimensional material, where the modification can be caused by a binder, which is attached, for example, by covalent or non-covalent bonds, to the nanopore to form the modified nanopore.
[0031] As used herein, the term "amphiphilic molecule" is a broad term and should be given its ordinary and customary meaning to those skilled in the art, and should not be limited to any special or special meaning. This term can refer, but is not limited to, in particular to any compound that contains two separate covalently bonded components with different affinities for solvents in the same molecule, one part having a high affinity for polar solvents (such as water) and another part having a strong affinity for non-polar solvents such as hydrocarbons, ethers, esters, etc. Surfactants, polymeric amphiphiles, and some lipid molecules that contain both hydrophilic and hydrophobic components are typical examples of amphiphilic molecules.
[0032] As used herein, the term "bilayer" is a broad term and should be given its ordinary and customary meaning to those skilled in the art and should not be limited to any special or particular meaning. The term can specifically refer to, but is not limited to, a membrane made of two layers of lipid molecules, preferably phospholipid molecules.
[0033] A "clinical diagnostic system" is a laboratory automation device dedicated to the analysis of samples for in vitro diagnostics. A clinical diagnostic system may have different configurations as needed and / or according to a desired laboratory workflow. Additional configurations are obtained by coupling several devices and / or modules together. A "module" is a work cell, typically smaller in size than the entire clinical diagnostic system, with a dedicated function. This function may be an analytical function, but also a pre-analytical or post-analytical function, or a subsidiary function of either a pre-analytical, analytical or post-analytical function. In particular, a module may be configured to cooperate with one or more other modules for performing a dedicated task of a sample processing workflow, for example by performing one or more pre-analytical and / or analytical and / or post-analytical steps. In particular, a clinical diagnostic system may comprise one or more analytical devices designed to perform respective workflows optimized for a particular type of analysis (e.g., clinical chemistry, immunochemistry, coagulation, hematology, liquid chromatography separation, mass spectrometry, etc.). Thus, a clinical diagnostic system may consist of one analytical device or any combination of such analytical devices with their respective workflows, where pre-analytical and / or post-analytical modules may be coupled to individual analytical devices or shared by several analytical devices. Alternatively, pre-analytical and / or post-analytical functions may be performed by units integrated into the analytical devices. A clinical diagnostic system may comprise functional units such as liquid handling units for pipetting and / or pumping and / or mixing of samples and / or reagents and / or system fluids, and may further comprise functional units for sorting, storage, transport, identification, separation, detection.
[0034] The clinical diagnostic system may include a nanopore holder, which is known to those skilled in the art and therefore will not be described in detail, but see, for example, Bhatti et al., RSC Adv., 2021, 11, 28996.
[0035] The clinical diagnostic system may further comprise a detector for detecting a frequency shift Δ between the first frequency and the second frequency.
[0036] The clinical diagnostic system may further comprise a converter or calculator for calculating the first frequency, the second frequency and / or the frequency shift from step e) from the time domain to the frequency domain, the converter being configured to use a transformation operation such as a Fourier transform.
[0037] A "sample preparation station" may be a pre-analytical module coupled to one or more analytical devices or a unit within an analytical device designed to perform a series of sample processing steps aimed at removing or at least reducing interfering matrix components in the sample and / or concentrating an analyte of interest in the sample. Such processing steps may include any one or more of the following processing operations performed sequentially, in parallel, or alternating on a sample or on multiple samples: pipetting (aspirating and / or dispensing) fluids, pumping fluids, mixing with reagents, incubation at a specific temperature, heating or cooling, centrifugation, separation, filtration, sieving, drying, washing, resuspension, dispensing, transport, storage, etc.
[0038] A "kit" is any article of manufacture (e.g., package or container) that includes at least one reagent, such as a drug for the treatment of a disease, or a probe for specifically detecting a biomarker gene or protein of the invention. The kit is preferably advertised, distributed, or sold as a unit for carrying out the method of the invention. Typically, the kit may further include a carrier means compartmentalized to receive in tight confinement one or more container means, such as a vial, tube, or the like. In particular, each of the container means includes one of the separate elements used in the method of the first aspect. The kit may further include one or more other reagents, including, but not limited to, a reaction catalyst. The kit may further include one or more other containers containing additional materials, including, but not limited to, buffers, diluents, filters, needles, syringes, and instructions for use. A label may be affixed to the container to indicate that the composition is to be used in a particular application, and may include instructions for either in vivo or in vitro use. The computer program code may be provided on a data storage medium or device, such as an optical storage medium (e.g., a compact disc), or directly on a computer or data processing device. Additionally, the kit may contain standard amounts of biomarkers, as described elsewhere herein, for calibration purposes.
[0039] In this detailed description, reference to "one embodiment," "an embodiment," or "in an embodiment" means that the referenced feature is included in at least one embodiment of the technology in all its aspects according to the present disclosure. Moreover, separate references to "one embodiment," "an embodiment," or "embodiments" do not necessarily refer to the same embodiment. However, such embodiments are also not mutually exclusive unless otherwise stated and unless readily apparent to one of ordinary skill in the art. Thus, the technology in all its aspects according to the present disclosure can encompass any various combinations and / or integrations of the embodiments described herein.
[0040] Embodiment In a first aspect, the present invention provides a method for determining an analyte of interest by frequency detection, comprising: a) providing a nanopore, the nanopore embedded in a two-dimensional material, having a first resonant frequency f1 and a second resonant frequency f AC applying an AC current having a b) providing a modified nanopore, the modified nanopore being embedded in the two-dimensional material and having a second resonant frequency f2, and having an AC frequency f AC An AC current having a magnitude of f AC >f1>f2, the modified nanopore containing an analyte of interest; c) detecting a frequency shift Δ between the first frequency and the second frequency; and d) using the frequency shift Δ to determine the analyte of interest.
[0041] Here we describe the principle of detecting frequency changes of charged constructs trapped within nanopores in two-dimensional materials, e.g., lipid bilayers. Detection of tagged nanopore constructs (modified nanopores) is visible, demonstrating a very stable signal after switching from the time domain to the frequency domain.
[0042] Preferably, the "natural" or resonant frequencies (f1 and / or f2) of the 2D material-nanopore-construct are such that the driving AC frequency f1 and / or f2 are greater than or equal to the catastrophic event of resonant breakdown, meaning that the lipid bilayer will form properly but the pore construct will not be established. AC should not match.
[0043] The driving force can be a current drive or it can be a magnetic drive.
[0044] Alternatively, the nanopore itself can be used without a captured construct by covalently attaching proteins or non-specific binders to the nanopore itself.
[0045] According to step (a), a nanopore is provided. The nanopore is embedded in a two-dimensional material. The nanopore has a first resonant frequency f1. An AC frequency f AC An AC current having a magnitude of:
[0046] For the first resonant frequency, the abbreviations f1 and f1 may be used interchangeably.
[0047] In an embodiment of the first aspect of the present invention, a method for determining an analyte of interest by frequency detection comprises: a) providing a nanopore, the nanopore embedded in a two-dimensional material, having a first resonant frequency f1 and a second resonant frequency f AC applying an AC current having a b) providing a modified nanopore, the modified nanopore being embedded in the two-dimensional material and having a second resonant frequency f2, and having an AC frequency f AC An AC current having a magnitude of f AC >f1>f2, the modified nanopore containing an analyte of interest; c) detecting a frequency shift Δ between the first frequency and the second frequency, where Δ=|f2|-|f1|; and d) using the frequency shift Δ to determine the analyte of interest.
[0048] In an embodiment of the first aspect of the present invention, the first resonant frequency f1 is a resonant frequency of the nanopore.
[0049] In an embodiment of the first aspect of the present invention, the first resonant frequency f1 is a resonant frequency of a nanopore embedded in the two-dimensional material.
[0050] Preferably, there is more than one nanopore, for example, 2, 3, 4, or hundreds, or thousands, or millions of nanopores. The nanopores are provided on a well plate. The well plate is a semiconductor chip. The semiconductor chip can have 128k cells.
[0051] In principle, nanopores are known to those skilled in the art and will not be described in detail. Nanopores can be purchased from the company Genia Technologies. To measure the current through a nanopore, a complementary metal-oxide-semiconductor (CMOS) chip can be used, which contains, for example, 264 individually addressable electrodes. This chip was developed by Genia Technologies.
[0052] In an embodiment of the first aspect of the present invention, the nanopore comprises a pore having a pore diameter of less than 1000 nm, and preferably has a pore diameter of 2 nm to 20 nm.
[0053] In an embodiment of the first aspect of the invention, the nanopore is a protein nanopore or a solid-state nanopore.
[0054] In an embodiment of the first aspect of the present invention, the protein nanopore is α-hemolysin or Mycobacterium smegmatis porin A.
[0055] In an embodiment of the first aspect of the present invention, the protein nanopore is a synthetic membrane comprising MoS2, graphene, Si, SiNx and / or SiO2.
[0056] According to step (b), a modified nanopore is provided. The modified nanopore is embedded in a two-dimensional material. The modified nanopore has a second resonant frequency f2. The AC frequency f AC An AC current having f is applied. AC >f1>f2. The modified nanopore contains the analyte of interest. In particular, at AC frequency fAC The same AC current having the following formula is applied to both the nanopore and the modified nanopore:
[0057] In an embodiment of the first aspect of the present invention, an AC frequency f AC The measurements are parallelized in time and space and / or multiplexed in time and space.
[0058] In an embodiment of the first aspect of the present invention, an AC frequency f AC The measurements are carried out using electrical and / or magnetic measurements.
[0059] For AC frequency, f AC For the first resonant frequency, the abbreviations f1 and f2 may be used interchangeably. For the second resonant frequency, the abbreviations f2 and f2 may be used interchangeably. The resonant frequencies (f1 and / or f2) are also referred to as natural frequencies.
[0060] In an embodiment of the first aspect of the present invention, the second resonant frequency f2 is the resonant frequency of the modified nanopore.
[0061] In an embodiment of the first aspect of the present invention, the second resonant frequency f2 is the resonant frequency of a modified nanopore embedded in the two-dimensional material.
[0062] The modified nanopore or the modified nanopore embedded in a two-dimensional material may be referred to here, and throughout this disclosure, as a construct.
[0063] Preferably, more than one modified nanopore is provided, for example, 2, 3, 4, or hundreds or thousands of modified nanopores are provided. The modified nanopores are provided on a well plate.
[0064] In an embodiment of the first aspect of the invention, the modified nanopore and the nanopore are distinguished from each other by a modification. The modification may be a complex or construct that is captured within the nanopore to form the modified nanopore. Additionally or alternatively, the modification may be a binder that is attached to the nanopore to form the modified nanopore.
[0065] In an embodiment of the first aspect of the invention, the modified nanopore provided in step b) is produced by modifying the nanopore provided in step a).
[0066] In an embodiment of the first aspect of the invention, the modified nanopore is generated by an analyte containing construct trapped within the nanopore.
[0067] In an embodiment of the first aspect of the invention, the construct comprises an aptamer, an antibody, an antibody fragment, e.g. FAB, a non-specific binder, e.g. C18 and / or van der Waals interactions between an aromatic structure and the analyte, DNA, an enzyme, e.g. a polymerase, an ionic interaction, e.g. a positive and negative charge pair.
[0068] In an embodiment of the first aspect of the invention, the modified nanopore is produced by a binder attached to the nanopore.
[0069] In an embodiment of the first aspect of the present invention, the binder is covalently attached to the nanopore.
[0070] In an embodiment of the first aspect of the invention, the binder non-specifically attaches to the nanopore by non-covalent bonds, preferably by van der Waals forces.
[0071] In an embodiment of the first aspect of the present invention, the modified nanopore comprises a pore having a pore diameter of less than 1000 nm, preferably having a pore diameter of between 2 nm and 20 nm.
[0072] In an embodiment of the first aspect of the invention, the modified nanopore is a protein nanopore or a solid-state nanopore.
[0073] In an embodiment of the first aspect of the present invention, the modified protein nanopore is α-hemolysin or Mycobacterium smegmatis porin A.
[0074] In an embodiment of the first aspect of the present invention, the modified protein nanopore is a synthetic membrane comprising MoS2, graphene, Si, SiNx and / or SiO2.
[0075] In an embodiment of the first aspect of the present invention, the AC frequency is higher than the first resonant frequency and higher than the second resonant frequency. The first resonant frequency is higher than the second resonant frequency and lower than the AC frequency. The second resonant frequency is lower than the first resonant frequency and lower than the first resonant frequency.
[0076] In an embodiment of the first aspect of the present invention, f AC >f1>f2 is |f AC |>|f1|>|f2|. In principle, the absolute values can be omitted, since the general meaning is that an increase in mass (e.g. nanopore or modified nanopore) directly translates into a lower resonant frequency, since the whole part becomes heavier.
[0077] In an embodiment of the first aspect of the present invention, the analyte of interest is a single molecule of the modified nanopore.Preferably, exactly one single molecule of the analyte is part of the modified nanopore.Thus, the method allows for the detection of a single molecule.
[0078] In an embodiment of the first aspect of the invention, the frequency shift is Δ=f2−f1, preferably Δ=|f2|−|f1|. In particular, both terms may be used interchangeably.
[0079] In an embodiment of the first aspect of the present invention, an AC frequency f ACis greater than 500Hz, or greater than 650Hz, or greater than 650Hz, or greater than 700Hz, or greater than 750Hz, for example 770Hz.
[0080] In an embodiment of the first aspect of the present invention, an AC frequency f AC is lower than 2000 Hz, or lower than 1700 Hz, or lower than 1500 Hz, or lower than 1300 Hz, or lower than 1000 Hz, for example 900 Hz.
[0081] In an embodiment of the first aspect of the present invention, the first and / or second frequency is between 400 Hz and 500 Hz. In principle, other first and / or second frequencies are possible depending on the type of analyte, nanopore and / or two-dimensional material of interest.
[0082] In an embodiment of the first aspect of the invention the two-dimensional material comprises amphiphilic molecules.In an embodiment of the first aspect of the invention the two-dimensional material is a bilayer, preferably a lipid bilayer.
[0083] In an embodiment of the first aspect of the present invention, the two-dimensional material is a monolayer, preferably comprising an amphiphilic molecule having two hydrophilic groups or two hydrophobic groups, more preferably two hydrophilic groups separated from each other by a hydrophobic group or two hydrophobic groups separated from each other by a hydrophilic group.
[0084] In an embodiment of the first aspect of the invention, the analyte of interest is a small molecule.
[0085] In an embodiment of the first aspect of the invention, the analyte of interest is a protein.
[0086] In an embodiment of the first aspect of the invention, the analyte of interest is selected from the group consisting of nucleic acids, amino acids, peptides, proteins, metabolites, hormones, fatty acids, lipids, carbohydrates, steroids, ketosteroids, secosteroids, molecules characterized by a specific modification of another molecule, substances internalized by an organism, metabolites of such substances, and combinations thereof.
[0087] In an embodiment of the first aspect of the invention, the method further comprises, before step c), the further step: e) detecting the voltage as a function of time across the nanopore provided in step a) and the modified nanopore provided in step b); and / or f) calculating the first frequency, the second frequency and / or the frequency shift from step e) using a translation operation such as a Fourier transform from the time domain to the frequency domain.
[0088] In an embodiment of the first aspect of the invention, steps c) and d) are performed after steps a) and b). Preferably, step a) is performed before step b). More preferably, after the nanopore of step a) is provided, the nanopore provided in step a) is modified to form a modified nanopore provided in step b).
[0089] In an embodiment of the first aspect of the invention, the analyte comprises biological tissue, biological material, foodstuffs, polymers, paintings, archaeological remains, artificial bone, skin, urine, or blood.
[0090] In an embodiment of the first aspect of the invention, the analyte is a protein, such as TNT.
[0091] In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more keto groups is a ketosteroid. In certain embodiments of the first aspect of the invention, the ketosteroid is selected from the group consisting of testosterone, epitestosterone, dihydrotestosterone (DHT), desoxymethyltestosterone (DMT), tetrahydrogestrinone (THG), aldosterone, estrone, 4-hydroxyestrone, 2-methoxyestrone, 2-hydroxyestrone, 16-ketoestradiol, 16-alpha-hydroxyestrone, 2-hydroxyestrone-3-methyl ether, prednisone, prednisolone, pregnenolone, progesterone, dehydroepiandrosterone (DHEA), 17-hydroxypregnenolone, 17-hydroxyprogesterone, androsterone, epiandrosterone, Δ4-androstenedione, 11-deoxycortisol, corticosterone, 21-deoxycortisol, 11-deoxycorticosterone, allopregnanolone, and aldosterone.
[0092] In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more carboxyl groups is selected from the group consisting of Δ8-tetrahydrocannabinolic acid, benzoylecgonine, salicylic acid, 2-hydroxybenzoic acid, gabapentin, pregabalin, valproic acid, vancomycin, methotrexate, mycophenolic acid, montelukast, repaglinide, furosemide, telmisartan, gemfibrozil, diclofenac, ibuprofen, indomethacin, zomepirac, isoxepac, and penicillin. In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more carboxyl groups is an amino acid selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, glutamine, asparagine, histidine, serine, threonine, tyrosine, cysteine, tryptophan, alanine, isoleucine, leucine, methionine, phenylalanine, valine, proline, and glycine.
[0093] In an embodiment of the first aspect of the present invention, the analyte molecule comprising one or more aldehyde groups is selected from the group consisting of pyridoxal, N-acetyl-D-glucosamine, alcaftadine, streptomycin, and josamycin.
[0094] In an embodiment of the first aspect of the invention, the carbonyl group is a carbonyl ester group. In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more ester groups is selected from the group consisting of cocaine, heroin, Ritalin, aceclofenac, acetylcholine, amcinonide, amyloxate, amylocaine, anileridine, aranidipine, artesunate, and pethidine.
[0095] In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more anhydride groups is selected from the group consisting of cantharidin, succinic anhydride, trimellitic anhydride, and maleic anhydride.
[0096] In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more diene groups is a secosteroid. In an embodiment, the secosteroid is selected from the group consisting of cholecalciferol (vitamin D3), ergocalciferol (vitamin D2), calcifediol, calcitriol, tachysterol, lumisterol, and tacalcitol. In particular, the secosteroid is vitamin D, in particular vitamin D2 or D3, or a derivative thereof. In a particular embodiment, the secosteroid is selected from the group consisting of vitamin D2, vitamin D3, 25-hydroxyvitamin D2, 25-hydroxyvitamin D3 (calcifediol), 3-epi-25-hydroxyvitamin D2, 3-epi-25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D2, 1,25-dihydroxyvitamin D3 (calcitriol), 24,25-dihydroxyvitamin D2, 24,25-dihydroxyvitamin D3. In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more diene groups is selected from the group consisting of vitamin A, tretinoin, isotretinoin, alitretinoin, natamycin, sirolimus, amphotericin B, nystatin, everolimus, temsirolimus, and fidaxomicin.
[0097] In an embodiment of the first aspect of the invention, the analyte molecule comprises a single hydroxyl group or two hydroxyl groups. In an embodiment where more than one hydroxyl group is present in the analyte molecule, the two hydroxyl groups may be located adjacent to each other (1,2-diol) or separated by one, two or three C atoms (1,3-diol, 1,4-diol, 1,5-diol, respectively). In a particular embodiment of the first aspect, the analyte molecule comprises a 1,2-diol group. In an embodiment where only one hydroxyl group is present, the analyte is selected from the group consisting of primary alcohols, secondary alcohols and tertiary alcohols. In an embodiment of the first aspect of the invention where the analyte molecule comprises one or more hydroxyl groups, the analyte is selected from the group consisting of benzyl alcohol, menthol, L-carnitine, pyridoxine, metronidazole, isosorbide mononitrate, guaifenesin, clavulanic acid, miglitol, zalcitabine, isoprenaline, acyclovir, methocarbamol, tramadol, venlafaxine, atropine, clofedanol, alpha-hydroxyalprazolam, alpha-hydroxytriazolam, lorazepam, oxazepam, temazepam, ethyl glucuronide, ethylmorphine, morphine, morphine-3-glucuronide, buprenorphine, codeine, dihydrocodeine, p-hydroxypropoxyphene, O-desmethyltramadol, desmetramadol, dihydroquinidine, and quinidine.In an embodiment of the first aspect of the invention, where the analyte molecule comprises more than one hydroxyl group, the analyte is selected from the group consisting of vitamin C, glucosamine, mannitol, tetrahydrobiopterin, cytarabine, azacytidine, ribavirin, floxuridine, gemcitabine, streptozotocin, adenosine, vidarabine, cladribine, estriol, trifluridine, clofarabine, nadolol, zanamivir, lactulose, adenosine monophosphate, idoxuridine, regadenoson, lincomycin, clindamycin, canaglyph. Rosin, tobramycin, netilmicin, kanamycin, ticagrelor, epirubicin, doxorubicin, arbekacin, streptomycin, ouabain, amikacin, neomycin, framycetin, paromomycin, erythromycin, clarithromycin, azithromycin, vindesine, digitoxin, digoxin, metrizamide, acetyldigitoxin, deslanoside, fludarabine, clofarabine, gemcitabine, cytarabine, capecitabine, vidarabine, and plicamycin.
[0098] In an embodiment of the first aspect of the invention, the analyte molecule comprises one or more thiol groups as functional groups, including but not limited to alkylthiol groups and arylthiol groups. In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more thiol groups is selected from the group consisting of thiomandelic acid, DL-captopril, DL-thiorphan, N-acetylcysteine, D-penicillamine, glutathione, L-cysteine, zofenoprilat, tiopronin, dimercaprol, succimer.
[0099] In an embodiment of the first aspect of the present invention, the analyte molecule comprises one or more disulfide groups as functional groups.In an embodiment of the first aspect of the present invention, the analyte molecule comprising one or more disulfide groups is selected from the group consisting of glutathione disulfide, dipyrithione, selenium sulfide, disulfiram, lipoic acid, L-cystine, fursultiamine, octreotide, desmopressin, vapreotide, terlipressin, linaclotide, and peginesatide.The selenium sulfide can be selenium disulfide, SeS2, or selenium hexasulfide, Se2S6.
[0100] In an embodiment of the first aspect of the invention, the analyte molecule comprises one or more epoxide groups as functional groups. In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more epoxide groups is selected from the group consisting of carbamazepine-10,11-epoxide, carfilzomib, furosemide epoxide, fosfomycin, sevelamer hydrochloride, cerulenin, scopolamine, tiotropium, tiotropium bromide, methylscopolamine bromide, eplerenone, mupirocin, natamycin, and troleandomycin.
[0101] In an embodiment of the first aspect of the invention, the analyte molecule comprises one or more phenolic groups as functional groups. In a particular embodiment of the first aspect of the invention, the analyte molecule comprising one or more phenolic groups is a steroid or steroid-like compound. In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more phenolic groups is a sp 2It is a steroid or steroid-like compound having a hybrid A-ring and an OH group at position 3 of the A-ring. In certain embodiments of the first aspect of the invention, the steroid or steroid-like analyte molecule is selected from the group consisting of estrogen, estrogenic compounds, estrone (E1), estradiol (E2), 17a-estradiol, 17b-estradiol, estriol (E3), 16-epiestriol, 17-epiestriol, and 16,17-epiestriol and / or metabolites thereof. In embodiments, the metabolite is estriol, 16-epiestriol (16-epiE3), 17-epiestriol (17-epiE3), 16,17-epiestriol (16,17-epiE3), 16-ketoestradiol (16-ketoE2), 16a-hydroxyestrone (16a-OHEl), 2-methoxyestrone (2-MeOEl), 4-methoxyestrone (4-MeOEl), 2-hydroxyestrone-3-methyl ether (3-MeOEl), 2-methoxyestradiol (2-MeOE2), 4-methoxyestradiol (4-MeOE2), 2-hydroxyestrone (2-OHE1), 4-hydroxyestrone (4- OHE1), 2-hydroxyestradiol (2-OHE2), estrone (El), estrone sulfate (Els), 17a-estradiol (E2a), 17b-estradiol (E2B), estradiol sulfate (E2S), equilin (EQ), 17a-dihydroequilin (EQa), 17b-dihydroequilin (EQb), equilenin (EN), 17-dihydroequilenin (ENa), 17α-dihydroequilenin, 17β-dihydroequilenin (ENb), Δ8,9-dihydroestrone (dEl), Δ8,9-dihydroestrone sulfate (dEls), Δ9-tetrahydrocannabinol, mycophenolic acid. β or b can be used interchangeably. α and a can be used interchangeably.
[0102] In an embodiment of the first aspect of the invention, the analyte molecule comprises an amine group as a functional group. In an embodiment of the first aspect of the invention, the amine group is an alkylamine group or an arylamine group. In an embodiment of the first aspect of the invention, the analyte comprising one or more amine groups is selected from the group consisting of proteins and peptides. In an embodiment of the first aspect of the invention, the analyte molecule comprising an amine group is selected from the group consisting of 3,4-methylenedioxyamphetamine, 3,4-methylenedioxy-N-ethylamphetamine, 3,4-methylenedioxymethamphetamine, amphetamine, methamphetamine, N-methyl-1,3-benzodioxolylbutanamine, 7-aminoclonazepam, 7-aminoflunitrazepam, 3,4-dimethylmethcathinone, 3-fluoromethan ... Cathinone, 4-methoxymethcathinone, 4-methylethcathinone, 4-methylmethcathinone, amfepramone, butyrone, etcathinone, elephedrone, methcathinone, methylone, methylenedioxypyrovalerone, benzoylecgonine, dehydronorketamine, ketamine, norketamine, methadone, normethadone, 6-acetylmorphine, diacetylmorphine, morphine, norhydrocodone, oxycodone, oxymol phenylpropoxyphene, amitriptyline, clomipramine, dothiepin, doxepin, imipramine, nortriptyline, trimipramine, fentanyl, glycylxylidide, lidocaine, monoethylglycylxylidide, N-acetylprocainamide, procainamide, pregabalin, 2-methylamino-1-(3,4-methylenedioxyphenyl)butane, N-methyl-1,3-benzodioxolylbutanamine, 2-amino-1-(3,4-methylenedioxyphenyl)butane, 1,3-benzodioxolylbutanamine, normeperidine, O-destramadol, desmetramadol, tramadol, lamotrigine, theophylline, amikacin, gentamicin, tobramycin, vancomycin, methotrexate, gabapentin sisomicin, and 5-methylcytosine.
[0103] In an embodiment of the first aspect of the invention, the analyte molecule is a carbohydrate or a substance having a carbohydrate moiety, such as a glycoprotein or a nucleoside. In an embodiment of the first aspect of the invention, the analyte molecule is a monosaccharide, in particular selected from the group consisting of ribose, desoxyribose, arabinose, ribulose, glucose, mannose, galactose, fucose, fructose, N-acetylglucosamine, N-acetylgalactosamine, neuraminic acid, N-acetylneurominic acid, etc. In an embodiment, the analyte molecule is an oligosaccharide, in particular selected from the group consisting of disaccharides, trisaccharides, tetrasaccharides, polysaccharides. In an embodiment of the first aspect of the invention, the disaccharide is selected from the group consisting of sucrose, maltose, and lactose. In an embodiment of the first aspect of the invention, the analyte molecule is a substance comprising the above-mentioned monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide moiety.
[0104] In an embodiment of the first aspect of the invention, the analyte molecule comprises as a functional group an azide group selected from the group consisting of alkyl or aryl azides. In an embodiment of the first aspect of the invention, the analyte molecule comprising one or more azide groups is selected from the group consisting of zidovudine and azidocillin.
[0105] Such analyte molecules may be present in biological or clinical samples such as bodily fluids, e.g., blood, serum, plasma, urine, saliva, cerebrospinal fluid, etc., tissue or cell extracts. In embodiments of the first aspect of the invention, the analyte molecule is present in a biological or clinical sample selected from the group consisting of blood, serum, plasma, urine, saliva, cerebrospinal fluid, and dried blood spots. In some embodiments of the first aspect of the invention, the analyte molecule may be present in a purified or partially purified sample, e.g., a sample that is a purified or partially purified protein mixture or extract.
[0106] Surprisingly, it has been found that the present invention allows detection of frequency changes of charged constructs trapped in nanopores in lipid bilayers. By modulating the AC frequency, the "natural frequency" of the lipid bilayer / nanopore construct is driven to a higher frequency. It has been shown that detection of tagged nanopore constructs is visible and a very stable signal is observed after switching from the time domain to the frequency domain.
[0107] In an embodiment of the first aspect of the invention the modified nanopore comprises: - protein nanopores or solid-state nanopores, - Optionally, a binder, and - an analyte of interest,
[0108] In a second aspect, the present invention relates to the use of the method of the first aspect of the invention for determining an analyte of interest.
[0109] All embodiments described for the first aspect of the invention apply to the second aspect of the invention and vice versa.
[0110] In a third aspect, the present invention provides a modified nanopore for use in a method of the first aspect of the invention for determining an analyte of interest, comprising: - protein nanopores or solid-state nanopores, - Optionally, a binder, and - an analyte of interest, the modified nanopore containing the analyte.
[0111] All embodiments described for the first aspect of the invention and / or the second aspect of the invention apply to the third aspect of the invention and vice versa.
[0112] In a fourth aspect, the present invention provides an analytical system comprising: a nanopore embedded in a two-dimensional material and having a first resonant frequency f1 and an AC frequency f AC A nanopore to which an AC current having a modified nanopore, the modified nanopore being embedded in a two-dimensional material and having a second resonant frequency f2, the second resonant frequency f being at an AC frequency f AC and a modified nanopore to which an AC current having a f AC >f1>f2, the modified nanopore contains an analyte of interest; The analytical system is configured to detect a frequency shift Δ between the first frequency and the second frequency and to use the frequency shift Δ to determine the analyte of interest.
[0113] All embodiments mentioned for the first aspect of the invention and / or the second aspect of the invention and / or the third aspect of the invention apply to the fourth aspect of the invention and vice versa.
[0114] In an embodiment of the fourth aspect of the invention the analytical system is a clinical diagnostic system.
[0115] In a fifth aspect, the present invention relates to the use of an analytical system for determining an analyte of interest by frequency detection.
[0116] In an embodiment of the fourth aspect of the invention, the AC current is adapted or adjusted to the experimental conditions, e.g. buffer conditions, type of pore, type of analyte.
[0117] All embodiments described for the first aspect of the invention and / or the second aspect of the invention and / or the third aspect of the invention and / or the fourth aspect of the invention apply to the fifth aspect of the invention and vice versa.
[0118] In a sixth aspect, the present invention provides a kit suitable for carrying out the method of the first aspect of the invention, comprising: - one or more reagents for forming a two-dimensional material; - one or more reagents for forming a nanopore; - one or more reagents for forming a modified nanopore, and - optionally a component selected from the group consisting of calibrators, buffers, additives, consumables, evaluation algorithms, and combinations thereof.
[0119] All embodiments described for the first aspect of the invention and / or the second aspect of the invention and / or the third aspect of the invention, the fourth aspect of the invention and / or the fifth aspect of the invention apply to the sixth aspect of the invention and vice versa.
[0120] In a seventh aspect, the present invention relates to the use of the kit of the fifth aspect of the invention for determining an analyte of interest by frequency detection.
[0121] All embodiments mentioned for the first aspect of the invention and / or the second aspect of the invention and / or the third aspect of the invention, the fourth aspect of the invention, the fifth aspect of the invention and / or the sixth aspect of the invention apply to the seventh aspect of the invention and vice versa. In further embodiments, the present invention relates to the following aspects: 1. A method for determining an analyte of interest by frequency detection, comprising: a) providing a nanopore, the nanopore embedded in a two-dimensional material, having a first resonant frequency f1 and a second resonant frequency f AC applying an AC current having a b) providing a modified nanopore, the modified nanopore being embedded in the two-dimensional material and having a second resonant frequency f2, and having an AC frequency f AC An AC current having a magnitude of f AC >f1>f2, the modified nanopore containing an analyte of interest; c) detecting a frequency shift Δ between the first frequency and the second frequency; and d) using the frequency shift Δ to determine the analyte of interest.
[0122] 2. Before step c), further steps: e) detecting the voltage across the nanopore provided in step a) and the modified nanopore provided in step b) as a function of time; and f) calculating the first frequency, the second frequency, and / or the frequency shift from step e) from the time domain to the frequency domain using a translation operation, such as a Fourier transform.
[0123] 3. The method of any preceding embodiment, wherein the modified nanopore provided in step b) is generated by modifying the nanopore provided in step a).
[0124] 4. The method of any preceding embodiment, wherein the analyte of interest is a single molecule of the modified nanopore.
[0125] 5. The frequency shift is Δ=f2-f1 and / or the AC frequency f AC The method of any preceding embodiment, wherein the measuring is parallelized in time and space.
[0126] 6. AC frequency f AC The method of any preceding embodiment, wherein the frequency band is greater than 500 Hz, or greater than 650 Hz, or greater than 650 Hz, or greater than 700 Hz, or greater than 750 Hz, e.g., 770 Hz.
[0127] 7. AC frequency f AC The method of any preceding embodiment, wherein the frequency band is lower than 2000 Hz, or lower than 1700 Hz, or lower than 1500 Hz, or lower than 1300 Hz, or lower than 1000 Hz, e.g., 900 Hz.
[0128] 8. The method of any preceding embodiment, wherein the first and / or second frequency is between 400 Hz and 500 Hz.
[0129] 9. The method of any preceding embodiment, wherein the modified nanopore is generated by an analyte containing construct trapped within the nanopore.
[0130] 10. The method of any preceding embodiment, wherein the construct comprises an aptamer, an antibody, an antibody fragment, e.g., FAB, a non-specific binder, e.g., C18 and / or van der Waals interactions between an aromatic structure and the analyte, DNA, an enzyme, e.g., a polymerase.
[0131] 11. The method of any preceding embodiment, wherein the modified nanopore is produced by a binder attached to the nanopore.
[0132] 12. The method of any preceding embodiment, wherein the binder is covalently attached to the nanopore.
[0133] 13. The method of any preceding embodiment, wherein the binder is non-specifically attached to the nanopore by non-covalent bonds, preferably van der Waals forces.
[0134] 14. The method of any preceding embodiment, wherein the nanopore comprises a pore having a pore diameter of less than 1000 nm (preferably having a pore diameter of between 2 nm and 20 nm).
[0135] 15. The method of any preceding embodiment, wherein the nanopore is a protein nanopore or a solid-state nanopore.
[0136] 16. The method of any preceding embodiment, wherein the protein nanopore is α-hemolysin or Mycobacterium smegmatis porin A.
[0137] 17. The method of any preceding embodiment, wherein the protein nanopore is a synthetic membrane comprising MoS2, graphene, Si, SiNx, and / or SiO2.
[0138] 18. The method of any preceding embodiment, wherein the two-dimensional material comprises amphiphilic molecules.
[0139] 19. The method of any preceding embodiment, wherein the two-dimensional material is a bilayer, preferably a lipid bilayer.
[0140] 20. The method of any preceding embodiment, wherein the two-dimensional material is a monolayer, preferably comprising an amphiphilic molecule having two hydrophilic groups or two hydrophobic groups, more preferably wherein the two hydrophilic groups are separated from each other by a hydrophobic group, or wherein the two hydrophobic groups are separated from each other by a hydrophilic group.
[0141] 21. The method of any preceding embodiment, wherein the analyte of interest is a small molecule.
[0142] 22. The method of any preceding embodiment, wherein the analyte of interest is a protein.
[0143] 23. The method of any preceding embodiment, wherein the analyte of interest is selected from the group consisting of nucleic acids, amino acids, peptides, proteins, metabolites, hormones, fatty acids, lipids, carbohydrates, steroids, ketosteroids, secosteroids, molecules characterized by a particular modification of another molecule, substances internalized by an organism, metabolic products of such substances, and combinations thereof.
[0144] 24. The modified nanopore is - protein nanopores or solid-state nanopores, - Optionally, a binder, and - an analyte of interest.
[0145] 25. Use of the method of any preceding embodiment for determining an analyte of interest.
[0146] 26. A modified nanopore for use in the method of any preceding embodiment for determining an analyte of interest, comprising: - protein nanopores or solid-state nanopores, - Optionally, a binder, and - a modified nanopore containing an analyte of interest.
[0147] 27. An analytical system comprising: a nanopore embedded in a two-dimensional material and having a first resonant frequency f1 and an AC frequency f AC of an AC current is applied to the nanopore; a modified nanopore, the modified nanopore being embedded in a two-dimensional material and having a second resonant frequency f2, the second resonant frequency f being at an AC frequency f AC a modified nanopore to which an AC current having f AC >f1>f2, the modified nanopore contains an analyte of interest; The analytical system is configured to detect a frequency shift Δ between the first frequency and the second frequency and to determine the analyte of interest using the frequency shift Δ.
[0148] 28. Use of the analytical system of embodiment 27 for determining an analyte of interest by frequency detection.
[0149] 29. A kit suitable for carrying out the method of any preceding embodiment, comprising: - one or more reagents for forming a two-dimensional material; - one or more reagents for forming a nanopore; - one or more reagents for forming a modified nanopore (e.g., a tag), and - Optionally, a kit comprising a component selected from the group consisting of calibrators, buffers, additives, consumables (e.g., tips, pipettes), evaluation algorithms, and combinations thereof.
[0150] 30. Use of the kit of embodiment 29 for determining an analyte of interest by frequency detection.
[0151] Working Example The following examples are offered to illustrate, but not to limit, the invention claimed herein.
[0152] 1A shows a method according to a first aspect of the invention. A method according to one embodiment is shown. This is the general principle of an experimental current-driven readout of a modified nanopore (biotin-streptavidin-protein in a lipid bilayer), where a time-dependent readout is shown.
[0153] A nanopore 1 is provided, embedded in a two-dimensional material 2 (e.g., a lipid bilayer) and having a first resonant frequency f1. AC An AC current having a frequency f2 is applied to the nanopore 4, which in this case is the nanopore 1 adapted by modification. The modified nanopore 4 has a second resonant frequency f2. A low AC pulse is applied with a frequency near the natural frequency of the modified nanopore or the modified nanopore-2D material. The FID (free induction decay) of the oscillations is based on inertia.
[0154] As an example, an open nanopore 1 is electrically inserted into a lipid bilayer 2. On the trans side of the nanopore, a buffer solution contains streptavidin. After a period of time, an analyte of interest, such as a fab fragment 3 covalently attached to a modified oligonucleotide 5 with a biotin 7 label, is applied to the cis side of the nanopore. The Fab-oligostreptavidin molecule enters the nanopore, attaches to the streptavidin, and is unable to exit the nanopore. An AC frequency is applied throughout the experiment.
[0155] The modified nanopore 4 includes a nanopore 1 and an analyte of interest 3. The analyte of interest 3 can be, for example, a protein or a small molecule, and can be tagged with biotin 5. AC >f1>f2.
[0156] A frequency shift Δ between the first frequency and the second frequency is then detected and the analyte of interest is determined using the frequency shift Δ. In particular, the voltage as a function of time of the nanopore provided in step a) and the modified nanopore provided in step b) are detected and the first frequency, the second frequency and / or the frequency shift from step e) are calculated from the time domain to the frequency domain using a translation operation, e.g., a Fourier transform.
[0157] The modified nanopore can be prepared as follows: Figure 1B shows the tag used to generate a defined voltage level within the nanopore. It comprises or consists of a C3 spacer and thymidine. In principle, other tags are possible, e.g. DNA, RNA, peptides, etc. The nanopore can be alpha-hemolysin or a variant thereof. In principle, other nanopores suitable to "host" the construct are also possible. Examples of pore-forming proteins are alpha-hemolysin, erolysin, and MspA porin.
[0158] Figure 2 shows a method according to a first embodiment of the invention. Different from Figure 1A, Figure 2 illustrates a procedure in which a magnetic label (e.g. a magnetic nanoparticle) 10 is covalently attached to a nanopore 1 that is electrically inserted into a two-dimensional material (e.g. a lipid bilayer) 2. With assistance from an alternating magnetic field applied by Helmholtz coils 9, the magnetic label can apply an external switching magnetic field to the nanopore within the bilayer.
[0159] Figure 3 shows how the workflow works for a nanopore that is subject to an external field (magnetic or electric field) and thus distorted, resulting in a change in current. The free induction decay 11 after each external field switching event is acquired. The time domain in which the experiment is performed (preferably seconds) is transformed into the frequency domain using data processing methods such as FFT.
[0160] Figure 4 shows a method according to a first embodiment of the invention. This is the general principle of a possible current-driven readout of a modified nanopore (biotin-streptavidin-protein in a lipid bilayer), with a time-dependent readout shown. An open nanopore 1 is electrically inserted into the lipid bilayer 2. A FAB binding moiety is covalently attached to the nanopore, for example by an L-LNA support 13. An AC frequency is applied throughout the experiment. The terms "fab" and "FAB" may be used interchangeably. The terms "pore" and "nanopore" may be used interchangeably.
[0161] Figure 5A shows the raw signal (voltage vs. time) of a modified nanopore (biotin-streptavidin-protein in lipid bilayer) at an AC frequency of 770 Hz. The x-axis is represented as a time signal (0 corresponds to the beginning of the experiment and 1000 represents the end of the experiment). Region A is the open nanopore in the lipid bilayer, region B is the addition of biotin-oligonucleotide-FAB fragment molecules, and region C is the steady state of the chemical added in region B bound to streptavidin. Figure 5B shows the signal (amplitude vs. frequency) of each of the regions described in Figure 5A after Fourier transformation of the raw signal described in Figure 5A (FFT signal). A clear peak can be seen around 475 Hz, shifting from region A (481.8 Hz) through region B (477.1 Hz) to region C (474.1 Hz) in the steady state. A distinction between region A and region C can be seen.
[0162] Figure 6 shows the raw signal (voltage vs. time) and the FFT signal (amplitude vs. frequency) of an experiment similar to that in Figure 5. The FFT analysis was performed while increasing the time points used for the FFT analysis (from 100 seconds to 890 seconds). Since the FFT signal is unchanged, the quality of the spectrum can be improved by using multiple points for the FFT or by multiplying the resulting FFT spectrum.
[0163] Figure 7A shows the raw (voltage vs. time) and FFT (amplitude vs. frequency) signals of a modified nanopore (biotin-streptavidin-protein) in a lipid bilayer at an AC frequency of 770 Hz. The FFT spectrum from a particular raw data point has a peak at 472 Hz.
[0164] Figure 7B shows the raw signal (voltage vs. time) and the FFT signal (amplitude vs. frequency) of a modified nanopore (biotin-streptavidin-protein) in a lipid bilayer at an AC frequency of 770 Hz. The FFT spectrum from a different time point in the same experiment has exactly the same 472 Hz peak as Figure 7A. Therefore, we can assume that the signal is constant at the steady state of the nanopore.
[0165] 8A-8E show the raw (voltage vs. time) and FFT (amplitude vs. frequency) signals of a modified nanopore (biotin-streptavidin-protein) in a lipid bilayer at an AC frequency of 770 Hz.
[0166] In Figure 8A, the region of the open nanopore is processed by FFT analysis to obtain the open pore signal at 481 Hz.
[0167] In Figure 8B, the region of the open / closed nanopore intermediate, where the biotin tag is not captured by streptavidin within the pore, is processed by FFT analysis to obtain the open nanopore signal at 475 Hz.
[0168] In Figure 8C, a region of the open nanopore where the biotin-tagged FAB molecule has not bound and left the pore is processed by FFT analysis to obtain the open pore signal at 481 Hz.
[0169] In Figures 8D and 8E, the steady-state blocked pore region with streptavidin / biotin binding is processed by FFT analysis to obtain blocked nanopore signals at 474 Hz and 473 Hz, respectively.
[0170] Figures 9A-9C show the raw (voltage vs. time) and FFT (amplitude vs. frequency) signals of a modified nanopore (biotin-streptavidin-protein) in a lipid bilayer at an AC frequency of 1 Hz. The FFT spectra in Figures 9A-9C are shown at different time points and do not distinguish between experimental conditions, nor do they show the respective natural frequencies of the nanopore in the lipid bilayer. Therefore, it is necessary that the driving frequency > the natural frequency of the nanopore in the lipid bilayer.
[0171] Figures 10A-B show the raw (voltage vs. time) and FFT (amplitude vs. frequency) signals of a modified nanopore (biotin-streptavidin-protein) in a lipid bilayer driven with an AC frequency of 1000 Hz. The FFT spectra in Figures 10A-B at different time points (before and after the FAB-oligo-biotin molecules flow over the pore) cannot distinguish the experimental conditions (before and after the FAB-oligo-biotin molecules flow). This is represented by the same frequency of about 524 Hz observed before and after each FAB-oligo-biotin molecule flow. Therefore, in this case, the nanopores in the lipid bilayer exhibit their own characteristic frequency at about 524 Hz, even though the FAB-oligo-biotin molecules are not stored in the nanopores.
[0172] This patent application claims priority to European Patent Application No. 21210216.4, the contents of which are incorporated herein by reference. [Explanation of symbols]
[0173] 1. Nanopore 2 2D materials 3. Analyte or analyte binder of interest (e.g., FAB fragment) 4. Modified Nanopore 5 Polymers (e.g., oligonucleotides) 6 Streptavidin 7 Anchor tags (e.g., biotin) 8 Electrical Contacts 9 Helmholtz Coil 10 Magnetic tags (e.g., magnetic nanoparticles) 11 Free induction decay 12 Covalent bonds between polymers (e.g., DNA and / or proteins) 13 Rigid polymers (e.g., DNA)
Claims
1. A method for determining an analyte of interest (3) by frequency detection, comprising: a) providing a nanopore (1), said nanopore (1) being embedded in a two-dimensional material (2) and having a first resonant frequency f 1 and has an AC frequency f AC applying an AC current having a b) providing a modified nanopore (4), said modified nanopore (4) being embedded in said two-dimensional material (2) and having a second resonant frequency f 2 and the AC frequency f AC and applying the AC current having a f AC >f 1 >f 2 and the modified nanopore (4) containing the analyte of interest (3), c) detecting a frequency shift Δ between the first frequency and the second frequency, Δ=|f 2 |-|f 1 |, and d) determining the analyte of interest using the frequency shift Δ; The method includes:
2. Before step c), e) detecting the voltage across the nanopore (1) provided in step a) and across the modified nanopore (4) provided in step b) as a function of time; and f) calculating the first frequency, the second frequency and / or the frequency shift from step e) using a transformation operation such as a Fourier transform from the time domain to the frequency domain; The method of claim 1 further comprising:
3. 10. The method according to any one of the preceding claims, wherein the modified nanopore (4) provided in step b) is produced by modifying the nanopore (1) provided in step a).
4. 13. The method according to any one of the preceding claims, wherein the analyte of interest (3) is a single molecule of the modified nanopore (4).
5. The AC frequency f AC 10. The method of any one of the preceding claims, wherein the measurements are parallelized in time and space.
6. The AC frequency f AC is higher than 500 Hz, or higher than 650 Hz, or higher than 650 Hz, or higher than 700 Hz, or higher than 750 Hz, for example 770 Hz, and / or AC 5. A method according to any one of the preceding claims, wherein the frequency band is lower than 2000 Hz, or lower than 1700 Hz, or lower than 1500 Hz, or lower than 1300 Hz, or lower than 1000 Hz, for example 900 Hz.
7. 10. The method according to any one of the preceding claims, wherein the first frequency and / or the second frequency is between 400 Hz and 500 Hz.
8. 2. The method according to any one of the preceding claims, wherein the modified nanopore (4) is generated by an analyte containing construct trapped within the nanopore (1).
9. 2. The method according to any one of the preceding claims, wherein the modified nanopore (4) is produced by a binder attached to the nanopore (1).
10. 2. The method of any one of the preceding claims, wherein the binder is covalently attached to the nanopore (1).
11. 10. The method according to any one of claims 1 to 9, wherein the binder non-specifically attaches to the nanopore (1) by non-covalent bonds, preferably by van der Waals forces.
12. Use of the method according to any one of claims 1 to 11 for determining the analyte of interest (3).
13. A modified nanopore (4) for use in the method according to any one of claims 1 to 11 for determining the analyte of interest (3), comprising: - protein nanopores or solid-state nanopores, - optionally a binder, and - said analyte of interest, A modified nanopore comprising (4).
14. 1. An analytical system comprising: a nanopore (1), said nanopore (1) being embedded in a two-dimensional material (2) and having a first resonant frequency f 1 and has an AC frequency f AC A nanopore (1) to which an AC current having a modified nanopore (4), said modified nanopore (4) being embedded in said two-dimensional material (2) and having a second resonant frequency f 2 and the AC frequency f AC a modified nanopore (4) to which the AC current having Equipped with f AC >f 1 >f 2 and the modified nanopore (4) containing the analyte of interest (3); The analytical system is configured to detect a frequency shift Δ between the first frequency and the second frequency and to determine the analyte of interest (3) using the frequency shift Δ. Analysis system.
15. 15. Use of an analytical system according to claim 14 for determining an analyte of interest (3) by frequency detection.
16. A kit suitable for carrying out the method according to claims 1 to 11, comprising: - one or more reagents for forming said two-dimensional material (2), one or more reagents for forming said nanopore (1), - one or more reagents for forming said modified nanopore (4), and - optionally a component selected from the group consisting of calibrators, buffers, additives, consumables, evaluation algorithms, and combinations thereof; Kit including:
17. 17. Use of the kit according to claim 16 for determining an analyte of interest (3) by frequency detection.
